Stephens analyst Jeff Garro lowered the firm’s price target on OptimizeRx (OPRX) to $17 from $20 and keeps an Equal Weight rating on the shares. Noting that shares are up greater than 200% year-to-date, the firm views the current risk/reward as balanced and looks to confirm business momentum exceeding conservative pipeline assumptions.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX: